272 related articles for article (PubMed ID: 25573098)
41. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin.
Muñoz-Montaño W; Muñiz-Hernández S; Avilés-Salas A; Catalán R; Lara-Mejía L; Samtani-Bassarmal S; Cardona AF; Mendoza-Desión J; Hernández-Cueto D; Maldonado A; Baay-Guzmán G; Huerta-Yepes S; Arrieta O
BMC Cancer; 2021 Aug; 21(1):892. PubMed ID: 34353292
[TBL] [Abstract][Full Text] [Related]
42. Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival.
Zito Marino F; Baselice S; Erra S; Ronchi A; Montella M; Morgillo F; Vicidomini G; Santini M; Poziello G; Cozzolino I; Accardo M; Franco R
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):231-238. PubMed ID: 32842027
[TBL] [Abstract][Full Text] [Related]
43.
Guo N; Zhang W; Zhang B; Li Y; Tang J; Li S; Zhao Y; Zhao Y; Xia H; Yu C
Mol Clin Oncol; 2015 Sep; 3(5):1123-1128. PubMed ID: 26623063
[TBL] [Abstract][Full Text] [Related]
44. Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery.
Yokomise H; Liu D; Chang S; Go T; Ishikawa S; Misaki N; Nakashima N
Anticancer Res; 2013 Mar; 33(3):1107-15. PubMed ID: 23482788
[TBL] [Abstract][Full Text] [Related]
45. Predictive and Prognostic Value of TUBB3, RRM1, APE1, and Survivin Expression in Chemotherapy-Receiving Patients with Advanced Non‑Small Cell Lung Cancer.
Raungrut P; Tanyapattrapong S; Jirapongsak J; Geater SL; Thongsuksai P
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3003-3013. PubMed ID: 37774051
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical comparison of biomarker expression in biopsy and surgical specimens of non-small cell lung cancer.
Okimoto T; Tsubata Y; Sutani A; Fuchita H; Koba N; Hotta T; Hamaguchi M; Miura K; Hamaguchi S; Ohe M; Kuraki T; Harada Y; Maruyama R; Miyamoto N; Kishimoto K; Isobe T
Anticancer Res; 2014 Jun; 34(6):2755-61. PubMed ID: 24922636
[TBL] [Abstract][Full Text] [Related]
47. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
[TBL] [Abstract][Full Text] [Related]
48. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
Chiappori AA; Zheng Z; Chen T; Rawal B; Schell MJ; Mullaney BP; Bepler G
J Thorac Oncol; 2010 Apr; 5(4):484-90. PubMed ID: 20107425
[TBL] [Abstract][Full Text] [Related]
49. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Valsecchi ME; Holdbrook T; Leiby BE; Pequignot E; Littman SJ; Yeo CJ; Brody JR; Witkiewicz AK
BMC Cancer; 2012 Mar; 12():104. PubMed ID: 22436573
[TBL] [Abstract][Full Text] [Related]
50. Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study.
Piljić Burazer M; Mladinov S; Matana A; Kuret S; Bezić J; Glavina Durdov M
Diagn Pathol; 2019 Sep; 14(1):105. PubMed ID: 31521181
[TBL] [Abstract][Full Text] [Related]
51. Individualized chemotherapy guided by the expression of
Li J; Sun P; Huang T; He S; Li L; Xue G
Oncol Lett; 2021 Jan; 21(1):21. PubMed ID: 33240427
[No Abstract] [Full Text] [Related]
52. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
Li Y; Wang LR; Chen J; Lou Y; Zhang GB
Dis Markers; 2014; 2014():960458. PubMed ID: 24591771
[TBL] [Abstract][Full Text] [Related]
53. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
54. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
[TBL] [Abstract][Full Text] [Related]
55. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
Zheng Z; Chen T; Li X; Haura E; Sharma A; Bepler G
N Engl J Med; 2007 Feb; 356(8):800-8. PubMed ID: 17314339
[TBL] [Abstract][Full Text] [Related]
56. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
57. Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
Lin CS; Liu TC; Lai JC; Yang SF; Tsao TC
Int J Med Sci; 2017; 14(13):1410-1417. PubMed ID: 29200955
[TBL] [Abstract][Full Text] [Related]
58. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
[TBL] [Abstract][Full Text] [Related]
59. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G
J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]